Beam Secures FDA Fast-Track for BEAM-302, Gains $5.9M ARK Investment
Beam Therapeutics secured FDA agreement to use 12-month AAT biomarker data in its BEAM-302 BLA, expediting its alpha-1 antitrypsin deficiency approval pathway and underpinning an H.C. Wainwright $80 price target implying 197% upside. ARK Invest added 218,529 shares worth $5.9M, bolstering market confidence.
1. FDA Expedited Approval Pathway
Beam Therapeutics reached an agreement with the U.S. FDA to leverage alpha-1 antitrypsin biomarker data over a 12-month period as the primary basis for its BEAM-302 Biologics License Application, accelerating the approval process for its alpha-1 antitrypsin deficiency therapy.
2. H.C. Wainwright Price Target
H.C. Wainwright maintained a Buy rating and set an $80 price target on Beam Therapeutics, implying approximately 197% upside potential based on its clinical progress and regulatory advancements.
3. Strong Cash Position
As of December 31, 2025, Beam held nearly $1.25 billion in cash and marketable securities, which management expects will finance ongoing operations, support BEAM-302 development, and fund the anticipated launch of its risto-cel therapy through 2029.
4. ARK Invest Share Acquisition
ARK Invest purchased 218,529 shares of Beam Therapeutics valued at roughly $5.9 million on February 13, following a 3.7% share gain, signaling growing institutional confidence in the company’s pipeline and strategic direction.